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Abstract
Background
Surveillance of congenital anomalies is important to identify potential teratogens.
Methods
This study analysed the prevalence of 61 congenital anomaly subgroups (excluding chro-
mosomal) in 25 population-based EUROCAT registries (1980–2012). Live births, fetal
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deaths and terminations of pregnancy for fetal anomaly were analysed with multilevel ran-
dom-effects Poisson regression models.
Results
Seventeen anomaly subgroups had statistically significant trends from 2003–2012; 12
increasing and 5 decreasing.
Conclusions
The annual increasing prevalence of severe congenital heart defects, single ventricle, atrio-
ventricular septal defects and tetralogy of Fallot of 1.4% (95% CI: 0.7% to 2.0%), 4.6% (1.0%
to 8.2%), 3.4% (1.3% to 5.5%) and 4.1% (2.4% to 5.7%) respectively may reflect increases in
maternal obesity and diabetes (known risk factors). The increased prevalence of cystic ade-
nomatous malformation of the lung [6.5% (3.5% to 9.4%)] and decreased prevalence of limb
reduction defects [-2.8% (-4.2% to -1.5%)] are unexplained. For renal dysplasia and maternal
infections, increasing trends may be explained by increased screening, and deceases in pat-
ent ductus arteriosus at term and increases in craniosynostosis, by improved follow up period
after birth and improved diagnosis. For oesophageal atresia, duodenal atresia/stenosis and
ano-rectal atresia/stenosis recent changes in prevalence appeared incidental when com-
pared with larger long term fluctuations. For microcephaly and congenital hydronephrosis
trends could not be interpreted due to discrepancies in diagnostic criteria. The trends for club
foot and syndactyly disappeared once registries with disparate results were excluded. No
decrease in neural tube defects was detected, despite efforts at prevention through folic acid
supplementation.
Introduction
Since thalidomide and rubella (German measles) were discovered as powerful teratogens [1,2],
congenital anomaly registries have been set up to facilitate research and surveillance concern-
ing environmental causes of congenital anomalies, and to provide early warning of new terato-
genic exposures[3]. The recent increases in the prevalence of microcephaly in South America
due to the infection of mothers with Zika virus during the first trimester of pregnancy, high-
lights the continued necessity of surveillance. [4–6] Most congenital anomalies are rare (for
instance spina bifida, one of the more common anomalies, only affects one baby in every 2,000
births) and therefore it is necessary to collect information on these anomalies across a large
population of births. A European network of population-based registries for the epidemiologic
surveillance of congenital anomalies (EUROCAT, http://www.eurocat-network.eu/) surveys
over 1.7 million births (29% of European birth population) per year from 38 high-quality mul-
tiple-source registries in 21 countries in Europe that ascertain congenital anomalies in termi-
nations of pregnancy and births [7–9]. The EUROCAT Central Registry performs annual
statistical monitoring for five and ten year pan-European trends in 25 registries [10–11]. This
paper presents the latest pan-European ten year trends (2003–2012) in 61 congenital anomaly
subgroups (chromosomal anomalies are excluded as recent trends in chromosomal anomalies
have already been reported) [12]. Anomalies that had significant increasing or decreasing
Trends in congenital anomalies in Europe from 1980 to 2012
PLOS ONE | https://doi.org/10.1371/journal.pone.0194986 April 5, 2018 2 / 18
trends are investigated in greater detail, by presenting the European prevalence over the past
32 years, and the prevalence and trends within each registry over the past ten years.
Methods
Data
All EUROCAT registries use multiple sources of information to ascertain cases in order to
cover all types of case (live birth, late fetal death (20+ weeks’ gestation), and termination of
pregnancy for fetal anomaly at any gestation). Data sources, depending on registry, include
maternity, neonatal, and paediatric records; fetal medicine, cytogenetic, pathology, and medi-
cal genetics records; specialist services including paediatric cardiology; and hospital discharge
and child health records [9]. All cases are coded to the International Classification of Diseases
(ICD) version 9 or 10 with 1-digit BPA extension. Cases can have one syndrome and up to
eight malformation codes. All coding is completed using the EUROCAT guide 1.3 with minor
anomalies being excluded [13].
In June 2014 anonymised aggregate data were extracted for all EUROCAT registries that
had a total birth prevalence of all anomalies (including chromosomal anomalies, genetic syn-
dromes and microdeletions) of over 2 per 100 pregnancies for the years from 2003–2012 and
had data for at least nine years of the time period from 2003 to 2012. Due to ICD-9 and ICD-
10 inconsistencies all registries must have used ICD10 coding for the whole ten year period
from 2003. Table 1 shows the 25 registries included and their birth prevalence of all anomalies
excluding chomosomal anomalies, genetic syndromes or microdeletions. Twenty one regis-
tries ascertained cases diagnosed up to at least 1 year of life and amongst these five registries
had no upper age limit for registration.
Anomalies monitored
All the anomaly subgroups that have been monitored are given in Fig 1. All cases with chromo-
somal anomalies, genetic syndromes or microdeletions were excluded from the analysis (trends
in the most common chromosomal anomalies have been recently reported elsewhere) [12].
Severe congenital heart defects (CHDs) have been defined as single ventricle, hypoplastic left
heart, hypoplastic right heart, Ebstein anomaly, tricuspid atresia, pulmonary valve atresia, com-
mon arterial truncus, atrioventricular septal defects (AVSD), aortic valve atresia/stenosis, trans-
position of great vessels, tetralogy of Fallot, total anomalous pulmonary venous return, and
coarctation of aorta. This was based on a previous EUROCAT study classifying CHDs into
three severity groups according to perinatal mortality rate [14].
Statistical methods for monitoring trends
The pan-European ten year trends in prevalence were examined for each congenital anomaly sub-
group separately, by fitting a multi-level Poisson regression model on the number of cases of the
anomaly each year within each registry, with the total number of births occurring in the area cov-
ered by the registry as the exposure. Random-effects models were used to account for potential
heterogeneity in reported prevalence across registries. Results are presented as a forest plot of the
average annual proportional change with its 95% Confidence Intervals (CI) in order to identify
potential trends that merit more detailed investigation.
For congenital anomaly subgroups with significant increasing or decreasing trends over ten
years, data over 32 years were also examined. Multilevel Poisson models were fitted for data
from 1980 to 2012, with each two years entered as a categorical variable and the registries as
strata. These models estimated (with 95% CI) the prevalence of each anomaly for each two
Trends in congenital anomalies in Europe from 1980 to 2012
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year period adjusted for registry, which was necessary as some registries did not have data for
the whole time period. The data were categorised into biannual categories for year of delivery,
in order to reduce the sampling errors.
For congenital anomaly subgroups with significant ten year trends, the prevalence of the
anomaly over the past ten years within each registry and its 95% CIs were then compared
using a forest plot. The European prevalence with its 99% CIs was plotted as a vertical band, to
enable visual comparison of the prevalence within each registry with the overall European esti-
mate. The 99% level of statistical significance was chosen for the European estimate, to be con-
sistent with the 99% CI funnel chosen below.
Funnel plots of the trend for each registry against the standard error of the trend were plotted
for congenital anomalies with significant trends for the last 10 years. The funnel plot is symmetri-
cal about the overall trend and visually allows for the precision of the estimates of the trends for
each registry to be taken into account, with smaller registries being more uncertain about the
trend, and hence higher up the axis and more likely to lie within the 99% interval, even though
their estimated trends could vary from the European average. The most precise estimates are near
the bottom of the graph. The two lines on the funnel plots creating the funnel are the 99% CIs of
the overall trend, so any registries which lie outside these funnels are not consistent with the Euro-
pean trend. The 99% level of statistical significance was chosen as, with 25 registries, we would
expect at least one registry to lie outside the 95% CI funnel, and only wanted to exclude from the
Table 1. EUROCAT registries included in the analysis: Total number of cases (excluding chromosomal anomalies) and births surveyed from 1980 to 2012 and prev-
alence per 100 births.
Years of data included Number
Registry Start Finish All cases with an anomaly Total births CA Prevalence per 100 births
Hainaut 1980 2012 7,892 378,359 2.1
Odense 1980 2012 3,705 173,987 2.1
Paris 1981 2012 24,820 1,057,400 2.3
Tuscany 1980 2012 12,308 686,687 1.8
Dublin 1980 2012 13,894 743,186 1.9
N Netherlands 1981 2012 11,480 530,580 2.2
Emilia Romagna 1981 2012 14,553 911,481 1.6
Vaud 1989 2012 5,628 182,403 3.1
Zagreb 1983 2012 2,932 191,023 1.5
Malta 1986 2011 2,861 116,098 2.5
S Portugal 1990 2011 3,276 321,290 1.0
Antwerp 1990 2012 7,803 362,889 2.2
Basque Country 1990 2011 6,450 380,871 1.7
Saxony Anhalt 1987 2012 9,576 369,795 2.6
Mainz 1990 2011 2,954 72,246 4.1
Cork and Kerry 1996 2012 3,167 151,415 2.1
Wales 1998 2012 16,435 501,720 3.3
Norway 1980 2012 24,538 836,535 2.9
Isle de Reunion 2002 2012 3,567 160,551 2.2
Thames Valley 1991 2012 4,728 322,938 1.5
Wessex 1994 2012 7,110 524,372 1.4
East Midlands and South Yorkshire 1998 2012 17,066 998,655 1.7
Northern England 2000 2012 7,739 416,731 1.9
Hungary 1998 2011 36,906 1,251,751 2.9
SE Ireland 1997 2012 1,646 108,730 1.5
https://doi.org/10.1371/journal.pone.0194986.t001
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analysis registries that were extremely likely to be outliers. The red line on the funnel plot is the
line of no change in prevalence. The trend for each registry was only calculated for anomalies
with at least 10 cases over a ten year period. If there were more than one registry with insufficient
numbers of cases they were combined, and the trend for the combined registries was calculated
and given on Figs 2–10 as “Z”. The letters in the funnel plot correspond to those in the prevalence
plot, which can be used to identify the individual registries and, in particular, those included in
the “Z” category.
All analyses were performed using Stata software version 12.
Sensitivity analysis
To determine the influence of potential outliers, the analysis was repeated, excluding reg-
istries in which the prevalence over the last ten years was over five times greater than the
Fig 1. Annual change in prevalence (95% CI) from 2003 to 2012 across Europe according to anomaly group.
https://doi.org/10.1371/journal.pone.0194986.g001
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ten year European average or whose ten year trend was outside the 99% CI funnels. “Five
times greater” was chosen arbitrarily to determine outliers of the prevalence, because it
was expected that the prevalence in some registries would be statistically significantly
higher than the European average. The aim was to identify only those registries with cod-
ing likely to be inconsistent with the rest of Europe. The revised ten year trend was com-
pared with the original estimated trend.
Fig 2. Prevalence and annual average change in prevalence for microcephaly and severe congenital heart disease.
[A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red
line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in
prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear
trend open diamonds). Red line is no trend. Severe CHD includes single ventricle, hypoplastic left heart, hypoplastic
right heart, Ebstein anomaly, tricuspid atresia, pulmonary valve atresia, common arterial truncus, atrioventricular
septal defects, aortic valve atresia/stenosis, transposition of great vessels, tetralogy of Fallot, total anomalous pulmonary
venous return, and coarctation of aorta.
https://doi.org/10.1371/journal.pone.0194986.g002
Fig 3. Prevalence and annual average change in prevalence for single ventricle and atrioventricular septal defect.
[A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red
line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in
prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear
trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g003
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Interpretation of trends
Before interpreting any increase or decline in total prevalence as a true increase or decline in
risk, potential changes in data quality, ascertainment, screening or diagnostic methods were
considered. To investigate causality, other risk factors were also considered, such as maternal
age, parity, the co-occurrence of other anomalies, or whether the anomaly was isolated. The
results from these investigations are considered by the EUROCAT Steering Committee, when
deciding if an observed trend is likely to reflect a true change in prevalence. Full details of any
additional investigations performed are given in the EUROCAT Statistical Monitoring report
[15]. During this analysis, individual registries with either an unexpectedly low or high
Fig 4. Prevalence and annual average change in prevalence for tetralogy of fallot and patent ductus arteriosus. [A]
European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red line)
[B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in
prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear
trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g004
Fig 5. Prevalence and annual average change in prevalence for congenital cystic adenomatous malformation of
lung and oesophageal atresia. [A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line)
and trend excluding outliers (red line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry
(95% CI) [C] Annual change in prevalence for 2003–2012: European (black line and 99% CI funnel) and registry
(linear trend black dots, non-linear trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g005
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prevalence were identified. The registries in question have all been contacted and will report
back to EUROCAT Central Registry, but further investigation into these discrepancies is
beyond the scope of this paper. The sensitivity analyses allow the reader to determine their rel-
ative influence on the overall results.
Results
Fig 1 presents the ten year trends according to the 61 congenital anomaly subgroups for all reg-
istries combined. There were 17 anomaly subgroups with significant trends at the 5% level of
significance; 12 increasing (severe CHD, single ventricle, atrioventricular septal defects,
Fig 6. Prevalence and annual average change in prevalence for duodenal atresia or stenosis and ano-rectal atresia
and stenosis. [A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding
outliers (red line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C]
Annual change in prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black
dots, non-linear trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g006
Fig 7. Prevalence and annual average change in prevalence for renal dysplasia and congenital hydronephrosis. [A]
European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red line)
[B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in
prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear
trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g007
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tetralogy of Fallot, cystic adenomatous malformation of lung, oesophageal atresia, duodenal
atresia/stenosis, ano-rectal atresia/stenosis, renal dysplasia, club foot, craniosynostosis and
maternal infections resulting in malformations) and five decreasing (microcephaly, patent
ductus arteriosus, congenital hydronephrosis, limb reduction and syndactyly). The prevalence
of neural tube defects as a group, and spina bifida and anencephaly individually, have shown
only a very slight non-significant reduction in the past ten years.
Table 2 gives the estimates of the European prevalence and trends (including all registries
and excluding outliers) from 2003 to 2012 of the 17 anomaly subgroups identified in Fig 1. A
brief summary of the interpretation of the observed trends is also given, with more details
Fig 8. Prevalence and annual average change in prevalence for limb reduction defects and club foot–congenital
talipes equinovarus. [A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend
excluding outliers (red line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI)
[C] Annual change in prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend
black dots, non-linear trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g008
Fig 9. Prevalence and annual average change in prevalence for syndactyly and craniosynostosis. [A] European
Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red line) [B]
Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in
prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear
trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g009
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provided when each anomaly subgroup is described below. The S1 table describes each of
these anomalies and details any external factors, such as changes in coding or the increased use
of prenatal ultrasound scans or changes in screening, that might affect the interpretation of
any trends detected.
Microcephaly
Fig 2 panel B shows the prevalence in Saxony Anhalt was more than five times the European
prevalence (due to a more lenient definition of the reduction in brain size judged to be micro-
cephalic), and therefore the data from Saxony Anhalt were subsequently excluded from the
trend analysis. The two registries that had the most inconsistent trends compared with the
European trend were Isle de la Reunion (increasing more than expected) and Dublin (decreas-
ing more than expected). Excluding Saxony Anhalt (due to its high prevalence) and the five
registries that were outside the 99% grey funnel from the trend analysis (panel C) caused the
estimated trend to have a slightly greater decrease, and the overall prevalence to be signifi-
cantly lower (panel A). This data on the prevalence of microcephaly in EUROCAT has been
published demonstrating that any changes in the prevalence of microcephaly due to the Zika
virus would be unlikely to be detected in most of Europe [16] due to the expected low preva-
lence of the Zika virus in most of Europe plus the discrepant prevalence in the registries shown
in Fig 1.
Severe CHD
Fig 2 shows that South Portugal and Zagreb had unexpectedly low prevalence of these anoma-
lies (panel B). Hungary had an unexpectedly high increase in prevalence (panel C), which
could be explained by its very low prevalence at the start of the ten year period. Due to data
protection and logistical issues, the ascertainment of cases of severe CHD in Dublin was
known to have decreased after 2009, which would explain the decreasing trend observed in
this register (panel C). Removal of Dublin and Hungary had a negligible effect on the Euro-
pean increasing trend estimate (panel A).
Single ventricle
Fig 3 shows the European prevalence is less than 1 per 10,000 births, which means that only
seven registries had sufficient cases to analyse the ten year trend individually. The cases from
the remaining registries were combined (Z symbol on Fig 3 panel C). The prevalence and
increasing trend was consistent amongst all registries.
Fig 10. Prevalence and annual average change in prevalence for maternal infections resulting in malformations.
[A] European Prevalence 1981–2012 (95% CI) with trend for 2003–2012 (black line) and trend excluding outliers (red
line) [B] Prevalence for 2003–2012: European (99% CI vertical grey line) and registry (95% CI) [C] Annual change in
prevalence for 2003–2012: European (black line and 99% CI funnel) and registry (linear trend black dots, non-linear
trend open diamonds). Red line is no trend.
https://doi.org/10.1371/journal.pone.0194986.g010
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Table 2. Prevalence of anomalies from 2003 to 2012, the annual proportional change during this period and the adjusted annual proportional change after exclud-
ing outliers for the 17 anomaly subgroups with statistically significant trends identified in Fig 1.
Birth prevalence per 10,000 births
(95% CI)
Annual proportional change in
prevalence (95% CI)
Interpretation of results after detailed investigations within registries
and consensus of EUROCAT Steering Committee (see S1 Table for
further details)Anomaly All
registries
Excluding outliers
(panel B in Figs 2–10)a
All
registries
Excluding outliers
(panel C in Figs 2–10) a
1: Microcephaly 2.00
(1.89–2.11)
1.25
(1.15–1.36)
-2.4%
(-4.4% to
-0.4%)
-2.9%
(-6.0% to 0.1%)
The diagnostic criteria must be standardised before the estimates of
prevalence or trend are interpreted.
2: Severe CHb 17.20
(16.87–
17.53)
17.08
(16.72–17.46)
1.4%
(0.7% to
2.0%)
1.1%
(0.3% to 1.9%)
There appears to be an increasing trend.
3: Single ventricle 0.63
(0.57–0.70)
0.63
(0.57–0.70)
4.6%
(1.0% to
8.2%)
4.6%
(1.0% to 8.2%)
There appears to be an increasing trend which will be monitored.
4: Atrioventricular septal
defect
1.80
(1.69–1.90)
1.82
(1.70–1.94)
3.4%
(1.3% to
5.5%)
3.1%
(0.8% to 5.4%)
There appears to be an increasing trend.
5: Tetralogy of Fallot 2.82
(2.69–2.95)
2.83
(2.69–2.98)
4.1%
(2.4% to
5.7%)
3.4%
(1.5% to 5.2%)
There appears to be an increasing trend.
6: Patent ductus arteriosus 3.64
(3.49–3.79)
2.50
(2.30–2.71)
-1.9%
(-3.4% to
-0.4%)
-3.8%
(-6.7% to -0.9%)
The slight decreasing trend is likely to have resulted from improved coding
of PDA rather than a true reduction in prevalence
7: Cystic adenomatous
malformation of lung
0.94
(0.87–1.02)
0.94
(0.87–1.02)
6.5%
(3.5% to
9.4%)
6.5%
(3.5% to 9.4%)
There appears to be an increasing trend.
8: Oesophageal atresia 2.21
(2.09–2.33)
2.22
(2.10–2.34)
2.3%
(0.4% to
4.2%)
2.8%
(0.8% to 4.7%)
The observed increasing trend should be interpreted with caution due to
variations in prevalence since 1981.
9: Duodenal atresia or stenosis 0.91
(0.84–0.99)
0.91
(0.84–0.99)
3.3%
(0.4% to
6.3%)
3.3%
(0.4% to 6.3%)
The observed increasing trend should be interpreted with caution due to
variations in prevalence since 1981.
10: Ano-rectal atresia and
stenosis
2.77
(2.64–2.90)
2.92
(2.78–3.07)
2.0%
(0.3% to
3.7%)
2.9%
(1.1% to 4.7%)
The observed increasing trend should be interpreted with caution due to
variations in prevalence since 1981.
11: Renal dysplasia 3.86
(3.71–4.02)
4.42
(4.25–4.60)
2.0%
(0.6% to
3.5%)
1.8%
(0.3% to 3.2%)
The observed increasing trend is likely to have resulted from increased
uptake of prenatal ultrasounds and not a true increase in prevalence.
12: Congenital hydronephrosis 9.78
(9.54–
10.03)
8.62
(8.32–8.92)
-1.5%
(-2.3% to
-0.6%)
-2.3%
(-3.5% to -1.0%)
The diagnostic criteria must be standardised before the estimates of
prevalence or trend are interpreted.
13: Limb reduction defects 4.50
(4.33–4.67)
4.49
(4.31–4.67)
-2.8%
(-4.2% to
-1.5%)
-3.6%
(-5.1% to -2.2%)
There appears to be a decreasing trend.
14: Club foot–talipes
equinovarus
10.84
(10.58–
11.10)
10.36
(9.96–10.77)
1.3%
(0.4% to
2.1%)
0.5%
(-0.9% to 1.9%)
The increasing trend is likely to have resulted from changes in reporting
rather than a true increase in prevalence.
15: Syndactyly 4.86
(4.69–5.04)
3.77
(3.59–3.96)
-2.8%
(-4.1% to
-1.5%)
-4.2%
(-5.9% to -2.4%)
The decreasing trend is likely to have resulted from improved coding
rather than a true decrease in prevalence.
16: Craniosynostosis 1.79
(1.68–1.90)
1.76
(1.65–1.87)
4.6%
(2.4% to
6.7%)
4.0%
(1.7% to 6.3%)
The observed increasing trend is likely to have resulted from improved
follow-up by the registries rather than a true increase in prevalence.
17: Maternal infections
resulting in malformations
0.65
(0.59–0.72)
1.19
(1.06–1.35)
3.9%
(0.4% to
7.4%)
0.9%
(-3.4% to 5.1%)
The observed increasing trend is likely to have resulted from increased
screening for CMV rather than a true increase in prevalence.
a: Outliers are those registries whose prevalence is 5 times greater than the European prevalence or whose trends lie outside of the 99% CI (grey funnel) in panel C in
Figs 2–10.
b: Severe CHD includes single ventricle, hypoplastic left heart, hypoplastic right heart, Ebstein anomaly, tricuspid atresia, pulmonary valve atresia, common arterial
truncus, atrioventricular septal defects, aortic valve atresia/stenosis, transposition of great vessels, tetralogy of Fallot, total anomalous pulmonary venous return, and
coarctation of aorta.
https://doi.org/10.1371/journal.pone.0194986.t002
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Atrioventricular septal defects (AVSD)
Fig 3 panel B shows the prevalence of AVSD was consistent across registries. As with severe
CHD, Hungary had an unexpectedly high increase in prevalence, which could be explained by
its very low prevalence at the start of the ten year period. There was a decreasing trend in
Northern England that was inconsistent with the European trend. Due to data protection and
logistical issues, the ascertainment of cases of AVSD in Dublin was known to have decreased
after 2009, which would explain the decreasing trend observed in this register. Removal of
Hungary and Northern England had a negligible effect on the European increasing trend
estimate.
Tetralogy of fallot (TOF)
Fig 4 shows the results were similar to those for severe CHD, Hungary again had a large
increasing trend and Dublin a decreasing trend that were not consistent with the European
trend. Removal of Dublin and Hungary had a negligible effect on the European increasing
trend estimate.
Patent ductus arteriosus (PDA)
Fig 4 shows the high prevalence in Saxony Anhalt, which is being investigated. In Norway, the
prevalence began to fall from 2007, and by 2011/12 it was 8 per 10,000, high but not exception-
ally so. Hungary again had a large increasing trend. After removal of the five outliers (Hun-
gary, Norway, East Midlands, Saxony Anhalt and the combined ten registries with small
numbers of cases (Z symbol panels B & C) a decreasing European trend remained.
Congenital cystic adenomatous malformation of lung (CCAM)
Fig 5 shows of the seven registries with the highest prevalence, five were from the UK. Only
nine registries had enough cases to enable trends in the prevalence across the ten years to be
examined. Data from the remaining registries were combined (point Z on the funnel plot
panel C). There was a consistent 6.5% increase in overall prevalence per annum. When exam-
ined separately isolated CCAM appeared to be increasing, however, CCAM in combination
with another major congenital anomaly in a different organ system did not (data not shown).
Oesophageal atresia
Fig 5 shows the prevalence was reasonably consistent across all EUROCAT registries. The
northern Netherlands was the only registry with an unexpectedly large decreasing trend. After
removal of the northern Netherlands, an increasing European trend remained.
Duodenal atresia or stenosis
Fig 6 shows the prevalence was so low that 13 registries had too few cases to analyse the trends
individually. There was an increasing trend in duodenal atresia or stenosis, with both the prev-
alence and the trend being consistent amongst all registries.
Ano-rectal atresia and stenosis
Fig 6 shows both Wessex and Emilia Romagna had decreasing trends that were inconsistent
with the overall trend, and after removing them from the analysis, the European increasing
trend became greater.
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Renal dysplasia
Fig 7 shows the prevalence was reasonably consistent across all EUROCAT registries; only
Hungary was an outlier, with an extremely low prevalence at the start of the ten year period,
and hence an extremely large increase over the ten year period. After removing Hungary from
the analysis, the European increasing trend remained.
Congenital hydronephrosis (CH)
Fig 7 shows there was considerable variation in CH prevalence across Europe, with Mainz,
Vaud and Wales being particularly high. There was a large number of registries that were not
consistent with the overall European trend, and when they were excluded, the prevalence dif-
fered considerably from the original estimate, with the European decreasing trend remaining.
Limb reduction defects
Fig 8 shows the prevalence was reasonably consistent across Europe. From 2004 there was a
decline in prevalence, although three registries (South Portugal, Basque country and Paris)
appeared to have had increasing trends that were significantly different from the overall trend,
and Emilia Romagna had a significantly greater decline than the overall decline.
Club foot–congenital talipes equinovarus (CTEV)
Fig 8 shows that there were several registries with inconsistent trends when compared with the
European average. Northern England only reported club foot if other anomalies were present,
isolated cases were not reported, hence the prevalence was low. When the data from the regis-
tries with inconsistent trends was removed, there was no longer an increasing trend in club
foot.
Syndactyly
Fig 9 shows there was a sudden decrease in prevalence and then a continued decrease. How-
ever the prevalence varied considerably between registries and there were several registries
with inconsistent trends when compared with the European average. Thames Valley was a
clear outlier, with a very strong increasing trend. This was due to increased diagnosis as a
result of raising awareness about syndactyly, due to a research project on Apert’s syndrome in
the area covered by the registry (syndactyly occurs in babies with Apert’s syndrome).
Craniosynostosis (CS)
Fig 9 shows there was a large disparity in prevalence between registries and three registries had
inconsistent trends compared with the average for Europe. After removal of the outliers the
increasing European trend remained.
Maternal infections resulting in malformations
Fig 10 shows the prevalence varied considerably between registries, with Antwerp having the
highest prevalence. Due to the extremely low prevalence, a large number of registries did not
have sufficient cases for the trend to be estimated individually, but when these registries were
combined (to form the Z group) the trend was increasing and inconsistent with the European
trend. Excluding these registries resulted in a considerably higher overall prevalence, because
all the registries with a low prevalence were excluded, and an increasing trend remained. The
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fetuses with maternal infections resulting in anomalies in EUROCAT were from mothers
infected with mainly cytomegalovirus, almost no rubella and a few toxoplasmosis.
Discussion
This study analysed the pan-European trends in prevalence in 25 different registries for 61 dif-
ferent congenital anomaly subgroups. We concluded that for five congenital anomaly subgroups
(severe CHD, single ventricle, AVSD, tetralogy of Fallot and cystic adenomatous malformation
of the lung) the observed increase in prevalence from 2003 to 2012 was likely to reflect a true
increase in prevalence, and that for limb reduction defects the observed decrease in prevalence
was likely to reflect a true decrease in prevalence. Three congenital anomaly subgroups (oeso-
phageal atresia, duodenal atresia/stenosis and ano-rectal atresia/stenosis) showed around an
annual 3% increase in prevalence. However, the ten year trends for these three anomalies have
been interpreted cautiously, as there have been very large fluctuations in prevalence over the
past 30 years for all three, and the current prevalence is similar to that in the 1990’s. The study
also observed trends in prevalence which were judged to be due to increased screening (renal
dysplasia and maternal infections), improved follow up and hence more accurate diagnosis
(PDA and craniosynostosis), changes in reporting (club foot), or changes in coding (syndactyly).
There were two anomaly subgroups for which the results were not interpreted due to defini-
tional differences between registries (microcephaly and congenital hydronephrosis). It is impor-
tant to establish routinely the difficulties in the surveillance of microcephaly in order to know
how to interpret any future increases in the prevalence, due to new infections such as the Zika
virus or other teratogenic exposures, or due to changes in case finding for microcephaly.
Severe CHD as a whole and single ventricle, AVSD and tetralogy of Fallot individually all
showed increases in prevalence. The European trend has been reported in an earlier paper [17]
using EUROCAT data to 2007. The model used in that paper estimated the trend in four year
and three year groups, for example, 2001 to2003 and 2004 to 2007. In this study we presented
data in two year groups. Hence the fall seen in our data from 2001/2 to 2003/4 and 2005/6 cor-
responds to the decrease from 2004 to 2007 in the previous study. Additional data available up
to 2012 shows that after a decrease from 2001/2 to 2003/4 there appeared to be an increasing
trend. The main risk factors identified for CHD are diabetes, increased body mass index
(BMI), smoking, alcohol consumption and the use of assisted reproductive technologies
(ART) [18–25]. The increases in diabetes, BMI and ART use in Europe may therefore explain
some of the observed increased prevalence [26]. Folic acid has been linked to reducing the risk
of CHD, but the evidence is inconclusive [23]. However, the prevalence of neural tube defects
(NTDs) (which are strongly associated with folic acid consumption) has not decreased and,
therefore, it is unlikely that any changes in folic acid consumption would have influenced the
trends in CHD.
The prevalence of cystic adenomatous malformation of the lung has increased in Europe,
partly due to the increased availability and quality of prenatal ultrasounds. However the preva-
lence and the increasing trends in prevalence were particularly high in England and Wales.
Since 2004 over 96% of pregnant women in the UK have been offered fetal anomaly scans at
18–22 weeks. The increasing trend may reflect an improvement in the quality of the scans.
Since 2007, in Northern Netherlands a 20 week prenatal ultrasound scan has been offered to
all pregnant women. However, cases with cystic adenomatous malformation of the lung are
only included if they are confirmed postnatally. There are no known risk factors for this anom-
aly, but further investigation will be required if the increasing trend continues.
The prevalence plot of limb reduction defects over time (Fig 8 panel A) shows a clear outlier
in 1989/90. This is due to several EUROCAT registries having a higher prevalence in these two
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years. Several studies at the time reported an association between limb reduction and early
chorion villus sampling (CVS) [27,28]and it was quickly recommended that CVS should not
be performed before 70 days gestation. It is likely that performing early CVS was responsible
for this temporary increase. There are no clear reasons for the observed decreases.
The prevalence of NTDs as a group and spina bifida and anencephaly individually showed
only a very slight non-significant reduction in the past ten years. The trends have been ana-
lysed in greater detail by Khoshnood et al [29]. Taking a folic acid supplement before concep-
tion and during the first trimester has been shown to reduce the prevalence of NTDs, and if
this health advice was being adopted by the majority of women we would have expected to see
reductions in the prevalences of these anomalies [30]. Mandatory fortification in many coun-
tries across the world has been shown to reduce the prevalence by up to 40% [31–34]. Such for-
tification should be urgently considered throughout Europe.
This study has a number of strengths, the main one being its size. Data were available on
250,000 congenital anomalies from 11.5 million births across Europe over 30 years. Many con-
genital anomalies are extremely rare, and therefore it is essential to combine data from many
registries to be able to determine whether the prevalence is changing. For example, in 16 regis-
tries there were too few cases of cystic adenomatous malformation of lung to derive a trend,
but when combined there is a very clear increasing trend. A further strength of the study was
the use of the EUROCAT Steering Committee in the interpretation of the data. It is essential
when analysing data from a large variety of sources covering a large range of anomalies that
the results are interpreted by a group of expert clinicians and epidemiologists, with detailed
knowledge of the individual registries over a long period of time. As a result of the Steering
Committee’s expert opinion and external information, out of the 17 statistically significant
trends observed, only six were considered to reflect true changes in prevalence.
The EUROCAT data analysed here covers 600,000 births per year, capturing around 10% of
all births in Europe. Caution should therefore be exercised in interpreting these results as rep-
resentative of Europe. A weakness of the study is that all the analyses depended on consistent
coding across all the registries. Guides and coding tips are regularly produced to help ensure
that this occurs [13]. However, for some anomalies, such as microcephaly, the large variation
in prevalence according to individual registries indicates that there remain differences in diag-
nosis of and discrepancies in coding practices for these congenital anomalies. Examining the
data in detail, as in this study, highlights these discrepancies and enables further coding advice
to be given. A further weakness of the analysis is that each anomaly was considered in isola-
tion. This is potentially unrealistic as anomalies from the same organ system may be likely to
have similar trends. For example, the patterns in prevalence of oesophageal atresia, duodenal
atresia or stenosis and ano-rectal atresia and stenosis all appear similar, and this should per-
haps be considered when analysing any of them individually.
This is the most comprehensive summary of congenital anomaly prevalence in Europe. We
have identified that there are still some congenital anomalies that are continuing to increase in
Europe, in particular severe CHDs. Risks factors for these anomalies include diabetes and obe-
sity, both of which are known to be increasing in Europe. Public health prevention policies
should therefore continue to focus on these two conditions. The issue of increasing obesity in
pregnancy is being addressed in the USA with the Healthy People 2020 including objective num-
ber 16.5 to increase the proportion of women entering pregnancy with a normal weight from
52.5% in 2007 to 57.8% by 2020.[35] The expected decrease in NTDs did not occur, and there-
fore the issue of adequate folic acid consumption needs to be addressed. The lack of observed
reductions in prevalence in any of the congenital anomaly subgroups (apart from limb reduc-
tion defects) indicates the importance of adopting the EUROCAT (European Surveillance of
Congenital Anomalies)/EUROPLAN Recommendations on policies to be considered for the
Trends in congenital anomalies in Europe from 1980 to 2012
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primary prevention of congenital anomalies in the European National Plans and Strategies on
Rare Diseases [36]
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